Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADH-1 + Melphalan ILI in Melanoma
NCT00421811Phase 2Completed
- Sponsor
- Adherex Technologies
- Start
- Apr 2007
- Primary completion
- Mar 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ADH-1 in Malignant Melanoma (MM), sponsored by Adherex Technologies. Primary endpoint: Best Overall Response according to unconfirmed RECIST at 12 weeks. Started Apr 2007; status: completed.
02
Drugs
ADH-1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00421811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421811.